1. LUNG TRANSPLANTATION Overall 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

2. NUMBER OF LUNG TRANSPLANTS REPORTED BY YEAR AND PROCEDURE TYPE NOTE: This figure includes only the lung transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as representing changes in the number of lung transplants performed worldwide. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

3. AVERAGE CENTER VOLUME Lung Transplants: January 1, 2000 - June 30, 2009 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

4. DISTRIBUTION OF TRANSPLANTS BY CENTER VOLUME Lung Transplants: January 1, 2000 - June 30, 2009 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

5. LUNG TRANSPLANTS: Transplant Recipient Age by Year of Transplant Transplants: January 1, 1987 – June 30, 2009 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

6. AGE DISTRIBUTION OF LUNG TRANSPLANT RECIPIENTS (1/1985-6/2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

7. AGE DISTRIBUTION OF LUNG TRANSPLANT RECIPIENTS BY ERA Transplants with unknown recipient age were excluded from this tabulation. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

8. LUNG TRANSPLANTS: Donor Age by Year of Transplant Transplants: January 1, 1987 – June 30, 2009 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

9. DONOR AGE DISTRIBUTION FOR LUNG TRANSPLANTS (1/1985-6/2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

10. DONOR AGE DISTRIBUTION FOR LUNG TRANSPLANTS BY ERA Transplants with unknown donor age were excluded from this tabulation. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

11. LUNG TRANSPLANTATION Adult Recipients 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

12. AGE DISTRIBUTION OF ADULT LUNG TRANSPLANT RECIPIENTS (1/1985-6/2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

13. AGE DISTRIBUTION OF ADULT LUNG TRANSPLANT RECIPIENTS BY ERA 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

14. AGE DISTRIBUTION OF ADULT LUNG TRANSPLANT RECIPIENTS BY ERA 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

15. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival (Transplants: January 1994 - June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

16. ADULT LUNG TRANSPLANTATION: Indications (1/1995-6/2009) DIAGNOSISSLT (N = 10,925)BLT (N = 15,013)TOTAL (N = 25,938) COPD/Emphysema5,249 ( 48.0% )3,967 ( 26.4% )9,216 ( 35.5% ) Idiopathic Pulmonary Fibrosis3,371 ( 30.9% )2,369 ( 15.8% )5,740 ( 22.1% ) Cystic Fibrosis197 ( 1.8% )3,964 ( 26.4% )4,161 ( 16.0% ) Alpha-1678 ( 6.2% )1,104 ( 7.4% )1,782 ( 6.9% ) Idiopathic Pulmonary Arterial Hypertension75 ( 0.7% )768 ( 5.1% )843 ( 3.3% ) Sarcoidosis221 ( 2.0% )448 ( 3.0% )669 ( 2.6% ) Bronchiectasis46 ( 0.4% )662 ( 4.4% )708 ( 2.7% ) LAM96 ( 0.9% )178 ( 1.2% )274 ( 1.1% ) Congenital Heart Disease34 ( 0.3% )195 ( 1.3% )229 ( 0.9% ) Re-Transplant: Obliterative Bronchiolitis209 ( 1.9% )173 ( 1.2% )382 ( 1.5% ) Obliterative Bronchiolitis (Not Re-Transplant) 57 ( 0.5% )174 ( 1.2% )231 ( 0.9% ) Re-Transplant: Not Obliterative Bronchiolitis114 ( 1.0% )140 ( 0.9% )254 ( 1.0% ) Connective Tissue Disease73 ( 0.7% )144 ( 1.0% )217 ( 0.8% ) Cancer5 ( 0.0% )19 ( 0.1% )24 ( 0.1% ) Other500 ( 4.6% )708 ( 4.7% )1,208 ( 4.7% ) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

17. ADULT LUNG TRANSPLANTATION: Distribution of Procedure Type for Major Indications (1993-2008) Year of TX Alpha-1COPDCystic FibrosisIPFIPAH DoubleSingleDoubleSingleDoubleSingleDoubleSingleDoubleSingle 199338.761.316.084.094.95.116.583.553.846.2 199443.057.018.981.186.113.914.086.063.536.5 199545.954.121.478.690.19.928.072.089.310.7 199647.352.726.972.987.013.027.472.682.018.0 199746.453.626.373.792.57.521.878.290.010.0 199848.551.529.071.092.77.320.080.086.813.2 199947.053.028.171.790.89.222.976.786.213.8 200057.742.329.270.894.75.331.768.392.77.3 200160.139.928.571.594.06.030.769.390.010.0 200256.643.438.661.496.23.835.264.889.910.1 200365.434.642.657.495.24.841.958.195.54.5 200473.925.445.454.696.23.844.655.494.55.5 200578.022.049.850.197.72.346.453.690.69.4 200676.323.758.541.399.20.849.450.6100.00.0 200786.913.164.835.297.12.948.951.194.06.0 200880.619.465.834.297.82.252.048.094.75.3 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

18. ADULT LUNG TRANSPLANTATION Procedure Type within Indication, by Year 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

19. ADULT LUNG TRANSPLANTATION: Indications for Single Lung Transplants (Transplants: January 1995 - June 2009) *Other includes: Sarcoidosis: 2.0% Bronchiectasis: 0.4% Congenital Heart Disease: 0.3% LAM: 0.9% OB (non-ReTx): 0.5% Miscellaneous:5.3% 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

20. ADULT LUNG TRANSPLANTATION: Indications for Bilateral/Double Lung Transplants (Transplants: January 1995 - June 2009) *Other includes: Sarcoidosis: 3.0% Bronchiectasis: 4.4% Congenital Heart Disease: 1.3% LAM: 1.2% OB (non-ReTx): 1.2% Miscellaneous:5.8% 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

21. ADULT LUNG TRANSPLANTATION Major Indications By Year (%) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

22. ADULT LUNG TRANSPLANTATION Major Indications By Year (Number) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

23. ADULT LUNG TRANSPLANTS: AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2009 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

24. ADULT LUNG TRANSPLANTS: DIAGNOSIS DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2009 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

25. ADULT LUNG TRANSPLANTS: DONOR AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2009 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

26. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: January 1988 – June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

27. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: January 1990 – June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

28. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Gender (Transplants: January 1990 – June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

29. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis (Transplants: January 1990 – June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

30. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 3 Months (Transplants: January 1990 – June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

31. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 1 Year (Transplants: January 1990 – June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

32. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival for Eisenmengers Syndrome (Transplants: January 1990 – June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

33. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Procedure Type (Transplants: January 1990 – June 2008) Diagnosis: Alpha-1 Antitrypsin Deficiency 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

34. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Procedure Type and Age (Transplants: January 1990 – June 2008) Diagnosis: Alpha-1 Antitrypsin Deficiency 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

35. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2008) Diagnosis: Emphysema/COPD 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

36. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Age (Transplants: January 1990 – June 2008) Diagnosis: Emphysema/COPD 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

37. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2008) Diagnosis: Idiopathic Pulmonary Fibrosis 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

38. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2008) Diagnosis: Idiopathic Arterial Pulmonary Hypertension 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

39. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2008) Diagnosis: Emphysema/COPD, Single Lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

40. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2008) Diagnosis: Emphysema/COPD, Double Lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

41. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2008) Diagnosis: Idiopathic Pulmonary Fibrosis, Single Lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

42. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2008) Diagnosis: Idiopathic Pulmonary Fibrosis, Double Lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

43. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Donor CMV status/Recipient CMV status (Transplants: October 1999 – June 2008) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

44. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Donor/Recipient CMV status (Follow-ups: July 2004 - June 2009) D(-)/R(-): N = 866 D(-)/R(+): N = 1,106 D(+)/R(-): N = 1,218 D(+)/R(+): N = 1,987 No comparisons were statistically significant at 0.05 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

45. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Donor/Recipient CMV status (Follow-ups: July 2004 - June 2009) 18-3435-4950-5960-6566+FemaleMale No comparisons were statistically significant at 0.05 except 50-59: D(+)/R(-) vs. D(+)/R(+) (p=0.0385) Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

46. ADULT LUNG TRANSPLANTS (1996-6/2008) Risk Factors for 1 Year Mortality (N=13,079) *Other = All diagnoses other than COPD, IPAH, IPF, cystic fibrosis, pulmonary fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, retransplant and LAM. Reference group = COPD/Emphysema, Single lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

47. ADULT LUNG TRANSPLANTS (1996-6/2008) Risk Factors for 1 Year Mortality (N=13,079) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

48. ADULT LUNG TRANSPLANTS (1996-6/2008) Risk Factors for 1 Year Mortality (N=13,079) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

49. ADULT LUNG TRANSPLANTS (1996-6/2008) Borderline Significant Risk Factors for 1 Year Mortality (N=13,079) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

50. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

51. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Recipient Age 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

52. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Center Volume 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

53. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Recipient Pre-Transplant Bilirubin 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

54. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Recipient Oxygen Required at Rest 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

55. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Recipient Pre-Transplant Cardiac Output 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

56. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Height Difference 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

57. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Recipient FEV1 (% predicted) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

58. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Recipient FVC (% predicted) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

59. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality (N=4,918) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

60. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = COPD/Emphysema Borderline Significant Risk Factors for 1 Year Mortality (N=4,918) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

61. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

62. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality Recipient Age 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

63. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality Center Volume 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

64. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality Recipient Oxygen Required at Rest 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

65. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality Recipient Pre-Transplant Cardiac Output 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

66. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality (N=3,124) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

67. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

68. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient Age 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

69. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Donor Weight 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

70. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient O 2 Required at Rest 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

71. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Center volume 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

72. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Ischemia Time 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

73. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient Bilirubin 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

74. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient FVC (% predicted) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

75. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient Pre-Transplant Cardiac Output 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

76. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient Creatinine at Transplant 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

77. ADULT LUNG TRANSPLANTS (1/1996-6/2008) Diagnosis = IPF Risk Factors for 1 Year Mortality Height Difference 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

78. ADULT LUNG TRANSPLANTS (1996-6/2004) Risk Factors for 5 Year Mortality (N=7,609) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

79. ADULT LUNG TRANSPLANTS (1996-6/2004) Risk Factors for 5 Year Mortality (N=7,609) Reference group = COPD/Emphysema, Single lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

80. ADULT LUNG TRANSPLANTS (1996-6/2004) Risk Factors for 5 Year Mortality (N=7,609) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

81. ADULT LUNG TRANSPLANTS (1996-6/2004) Borderline Significant Risk Factors for 5 Year Mortality (N=7,609) *Other = All diagnoses other than COPD, IPAH, IPF, cystic fibrosis, pulmonary fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, retransplant and LAM. Reference diagnosis group = COPD/Emphysema, Single lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

82. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

83. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Recipient Age 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

84. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Donor Age 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

85. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Center Volume 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

86. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Recipient Pre-Transplant Bilirubin 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

87. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Recipient Oxygen Required at Rest 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

88. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Recipient FEV1 (% predicted) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

89. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Recipient Pre-Transplant Cardiac Output 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

90. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Recipient Height 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

91. ADULT LUNG TRANSPLANTS (1996-6/2004) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=5,769) Reference group = COPD/Emphysema, Single lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

92. ADULT LUNG TRANSPLANTS (1996-6/2004) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=5,769) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

93. ADULT LUNG TRANSPLANTS (1996-6/2004) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=5,769) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

94. ADULT LUNG TRANSPLANTS (1996-6/2004) Borderline Significant Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=5,769) *Other = All diagnoses other than COPD, IPAH, IPF, cystic fibrosis, pulmonary fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, retransplant and LAM. Reference group = COPD/Emphysema, Single lung 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

95. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

96. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Recipient Age 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

97. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Center Volume 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

98. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Height Difference 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

99. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Donor Age 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

100. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Recipient Height 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

101. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Recipient Pre-Transplant Cardiac Output 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

102. ADULT LUNG TRANSPLANTS (1/1996-6/2004) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Recipient FEV1 (% predicted) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

103. ADULT LUNG RECIPIENTS Cross-Sectional Analysis Functional Status of Surviving Recipients (Follow-ups: April 1994 – June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

104. ADULT LUNG RECIPIENTS Longitudinal Analysis Functional Status of Surviving Recipients (Follow-ups: April 1994 – June 2009) For the Same Patients 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

105. ADULT LUNG RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: March 2005 - June 2009) US Recipients Only 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

106. ADULT LUNG RECIPIENTS Employment Status of Surviving Recipients (Follow-ups: April 1994 – June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

107. ADULT LUNG RECIPIENTS: Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: April 1994 - June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

108. ADULT LUNG RECIPIENTS Induction Immunosuppression (Transplants: January 2002 - June 2009) Analysis limited to patients receiving prednisone Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

109. ADULT LUNG RECIPIENTS Induction Immunosuppression (Transplants: 1997, 2002 and 1/2009-6/2009) Analysis limited to patients receiving prednisone Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

110. ADULT LUNG RECIPIENTS Induction Immunosuppression (Transplants: January 2000 - December 2008) Analysis limited to patients receiving prednisone Any Induction Polyclonal ALG/ATG IL2R-antagonist Campath Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

111. SURVIVAL BY INDUCTION USAGE For Adult Lung Recipients (Transplants: April 1994-June 2008) Conditional on survival to 14 days 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

112. SURVIVAL BY INDUCTION USAGE For Adult Lung Recipients (Transplants: January 2000-June 2008) Conditional on survival to 14 days 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

113. ADULT LUNG RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For follow-ups between January 2002 through June 2009 Analysis limited to patients receiving prednisone NOTE: Different patients are analyzed in Year 1 and Year 5 Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

114. ADULT LUNG RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For follow-ups between January 2002 through June 2009 Analysis limited to patients receiving prednisone NOTE: Different patients are analyzed in Year 1 and Year 5 Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

115. ADULT LUNG RECIPIENTS Maintenance Immunosuppression at Time of 1 Year Follow-up (Follow-ups: 2000, 2003, 7/2008 – 6/2009) Analysis limited to patients receiving prednisone NOTE: Different patients are analyzed in each time frame. Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

116. ADULT LUNG RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For follow-ups between January 2002 through June 2009 Analysis limited to patients receiving prednisone 1 Year Follow-up (N =7,234)5 Year Follow-up (N = 3,021) NOTE: Different patients are analyzed in Year 1 and Year 5 Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

117. ADULT LUNG RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For follow-ups between January 2002 through June 2009 Analysis limited to patients receiving prednisone Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

118. ADULT LUNG RECIPIENTS Kaplan-Meier Survival by Maintenance Immunosuppression Combinations Conditional on Survival to 1 Year (Transplants: January 2000-June 2008) Analysis limited to patients receiving prednisone 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

119. ADULT LUNG RECIPIENTS Kaplan-Meier Survival by Maintenance Immunosuppression Combinations Conditional on Survival to 1 Year (Transplants: January 2000-June 2008) Analysis limited to patients receiving prednisone Diagnosis: COPD/Emphysema 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

120. ADULT LUNG RECIPIENTS Kaplan-Meier Survival by Maintenance Immunosuppression Combinations Conditional on Survival to 1 Year (Transplants: January 2000-June 2008) Analysis limited to patients receiving prednisone Diagnosis: Idiopathic Pulmonary Fibrosis 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

121. ADULT LUNG RECIPIENTS Kaplan-Meier Survival by Maintenance Immunosuppression Combinations Conditional on Survival to 1 Year (Transplants: January 2000-June 2008) Analysis limited to patients receiving prednisone Diagnosis: Cystic Fibrosis 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

122. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up (Follow-ups: July 1, 2004 - June 30, 2009) Analysis is limited to patients who were alive at the time of the follow-up Overall: N = 5,672 18-34: N = 787 35-49: N = 1,005 50-59: N = 1,937 60-65: N = 1,514 66+: N = 429 Female: N = 2,540 Male: N = 3,132 Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

123. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Type of Induction (Follow-ups: July 1, 2004 - June 30, 2009) No induction: N = 2,624 Polyclonal: N = 502 IL2R- antagonist: N = 2,142 Campath: N = 358 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

124. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Type of Induction (Follow-ups: July 1, 2004 - June 30, 2009) 18-34: no induct vs. IL2 (p=0.0164); poly vs. IL2R (p=0.007); IL2R vs. Campath (p=0.0084) 35-49: no induct vs. Campath (p=0.0310); IL2R vs. Campath (p=0.0112; 50-59: no induct vs. IL2R (p=0.0005); 60-65: no induct vs. IL2R (p=0.0018); no induct vs. Campath (p=0.0100) 66+: no induct vs. poly (p=0.0014); poly vs. IL2 (p<0.0001); poly vs. Campath (p<0.0001) Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

125. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Type of Induction (Follow-ups: July 1, 2004 - June 30, 2009) Female: no induct vs. IL2R (p=0.0032); IL2R vs. Campath (p=0.0152) Male: no induct vs.IL2R (p<0.0001); poly vs. IL2R (p = 0.0011) Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti- rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

126. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Maintenance Immunosuppression (Follow-ups: July 1, 2004 - June 30, 2009) Cyclosporine + MMF: N = 371 Cyclosporine + AZA: N = 555 Tacrolimus + MMF: N = 2,476 Tacrolimus + AZA: N = 1,448 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

127. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Maintenance Immunosuppression (Follow-ups: July 1, 2004 - June 30, 2009) All age groups: all comparisons with CyA + AZA are significant at 0.02 except 35-49: CyA + AZA vs. CyA+ MMF (p=0.1033) and 66+: CyA + AZA vs. CyA + MMF (p=0.0850) 35-49: CyA + MMF vs. TAC + MMF( p=0.0260); CyA + MMF vs. TAC + AZA (p=0.0253) 50-59: CyA + MMF vs. TAC + MMF (p=0.0076) 60-65: CyA + MMF vs. TAC + MMF (p=0.0078); TAC + MMF vs. TAC + AZA (p=0.0022) 66+: TAC + MMF vs. TAC + AZA (p=0.0301) Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti- rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

128. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Maintenance Immunosuppression (Follow-ups: July 1, 2004 - June 30, 2009) Females: all comparisons are statistically significant at 0.01 except CyA + MMF vs. TAC + AZA (p=0.2562) Males: all comparisons were statistically significant at 0.01 except CyA +MMF vs. TAC + AZA (p=0.0590) and TAC + MMF vs. TAC + AZA (p=0.0922) Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti- rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

129. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 3-Year Follow-Up Stratified by Maintenance Immunosuppression (Follow-ups: July 1, 2004 - June 30, 2009) Cyclosporine + MMF: N = 188 Cyclosporine + AZA: N = 289 Tacrolimus + MMF: N = 909 Tacrolimus + AZA: N = 678 Analysis is limited to patients with rejection or no rejection reported on all three annual follow-ups through 3 years Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

130. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 3-Year Follow-Up Stratified by Maintenance Immunosuppression (Follow-ups: July 1, 2004 - June 30, 2009) All age groups and genders: all comparisons with CyA + AZA are significant at 0.02 except 35-49: CyA + AZA vs. CyA+ MMF (p=0.6121) and 66+: CyA + AZA vs. CyA + MMF (p=0.1044) 35-49: CyA + MMF vs. TAC + MMF (p=0.0515); CyA + MMF vs. TAC + AZA (p=0.0368); Analysis is limited to patients with rejection or no rejection reported on all three annual follow-ups through 3 years Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

131. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 Year Post-Transplant (Follow-ups: April 1994 - June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

132. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 and 5 Years Post-Transplant (Follow-ups: April 1994 - June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

133. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 10 Years Post-Transplant (Follow-ups: April 1994 - June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

134. FREEDOM FROM BRONCHIOLITIS OBLITERANS SYNDROME For Adult Lung Recipients (Follow-ups: April 1994-June 2009) Conditional on Survival to 14 days 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

135. FREEDOM FROM BRONCHIOLITIS OBLITERANS SYNDROME STRATIFIED BY INDUCTION USE For Adult Lung Recipients (Follow-ups: April 1994-June 2009) Conditional on Survival to 14 days 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

136. FREEDOM FROM BRONCHIOLITIS OBLITERANS SYNDROME Stratified by Donor CMV Status/Recipient CMV Status For Adult Lung Recipients (Follow-ups: April 1994-June 2009) Conditional on Survival to 14 days 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

137. FREEDOM FROM SEVERE RENAL DYSFUNCTION* For Adult Lung Recipients (Follow-ups: April 1994-June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

138. MALIGNANCY POST-LUNG TRANSPLANTATION FOR ADULTS Cumulative Prevalence in Survivors (Follow-ups: April 1994 - June 2009) Malignancy/Type1-Year Survivors5-Year Survivors10-Year Survivors No Malignancy 12,669 (96.4%)3,406 (87.0%)451 (71.8%) Malignancy (all types combined) 470 (3.6%)510 (13.0%)177 (28.2%) Malignancy Type* Skin 127306114 Lymph 1957231 Other 12915852 Type Not Reported 1980 * Recipients may have experienced more than one type of malignancy so sum of individual malignancy types may be greater than total number with malignancy. Other malignancies reported include: adenocarcinoma (2; 2; 1), bladder (2; 1; 0), lung (2; 4; 0), breast (1; 5; 2); prostate (0; 5; 1), cervical (1; 1; 0); liver (1; 1; 1); colon (1; 1; 0). Numbers in parentheses represent the number of reported cases within each time period. 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

139. FREEDOM FROM MALIGNANCY For Adult Lung Recipients (Follow-ups: April 1994-June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

140. ADULT LUNG TRANSPLANT RECIPIENTS: Cause Of Death (Deaths: January 1992- June 2009) CAUSE OF DEATH 0-30 Days (N = 1,966) 31 Days – 1 Year (N = 3,387) >1 Year – 3 Years (N = 3,073) >3 Years – 5 Years (N = 1,737 ) >5 Years – 10 Years (N = 2,014) >10 Years (N = 483) BRONCHIOLITIS6 (0.3%)159 (4.7%)781 (25.4%)508 (29.2%)507 (25.2%)95 (19.7%) ACUTE REJECTION74 (3.8%)61 (1.8%)48 (1.6%)10 (0.6%)15 (0.7%)1 (0.2%) LYMPHOMA1 (0.1%)86 (2.5%)63 (2.1%)28 (1.6%)46 (2.3%)23 (4.8%) MALIGNANCY, OTHER4 (0.2%)100 (3.0%)202 (6.6%)151 (8.7%)219 (10.9%)47 (9.7%) CMV096 (2.8%)29 (0.9%)5 (0.3%)4 (0.2%)0 INFECTION, NON-CMV396 (20.1%)1,205 (35.6%)710 (23.1%)329 (18.9%)363 (18.0%)81 (16.8%) GRAFT FAILURE557 (28.3%)589 (17.4%)591 (19.2%)327 (18.8%)379 (18.8%)87 (18.0%) CARDIOVASCULAR213 (10.8%)144 (4.3%)118 (3.8%)82 (4.7%)99 (4.9%)36 (7.5%) TECHNICAL162 (8.2%)76 (2.2%)18 (0.6%)8 (0.5%)12 (0.6%)6 (1.2%) OTHER553 (28.1%)871 (25.7%)513 (16.7%)289 (16.6%)370 (18.4%)107 (22.2%) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

141. ADULT LUNG TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January 1992 - June 2009) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

142. ADULT LUNG TRANSPLANT RECIPIENTS: Cause Of Death Stratified by Donor CMV Status/Recipient CMV Status (Deaths: January 1992- June 2009) Donor CMV Status/ Recipient CMV Status Cause of Death0-30 Days 31 Days – 1 Year >1 Year – 3 Years >3 Years – 5 Years >5 Years – 10 Years >10 Years D(-)/R(-) (N=1,421) BRONCHIOLITIS1 (0.5%)22 (6.3%)88 (24.6%)68 (32.4%)61 (24.0%)14 (21.5%) INFECTION, NON-CMV31 (16.9%)123 (35.0%)86 (24.0%)39 (18.6%)35 (13.8%)12 (18.5%) GRAFT FAILURE56 (30.6%)70 (19.9%)73 (20.4%)44 (21.0%)50 (19.7%)10 (15.4%) D(-)/R(+) (N=2,106) BRONCHIOLITIS3 (1.1%)26 (5.5%)126 (25.2%)89 (25.7%)111 (26.7%)20 (19.2%) INFECTION, NON-CMV56 (20.8%)188 (39.8%)122 (24.4%)81 (23.4%)67 (16.1%)20 (19.2%) GRAFT FAILURE81 (30.1%)78 (16.5%)94 (18.8%)58 (16.8%)86 (20.7%)20 (19.2%) D(+)/R(-) (N=1,741) BRONCHIOLITIS014 (2.6%)108 (24.0%)60 (25.6%)60 (24.8%)3 (5.8%) INFECTION, NON-CMV42 (18.3%)200 (37.5%)103 (22.9%)41 (17.5%)47 (19.4%)13 (25.0%) GRAFT FAILURE66 (28.8%)109 (20.4%)101 (22.4%)54 (23.1%)56 (23.1%)9 (17.3%) D(+)/R(+) (N=3,130) BRONCHIOLITIS1 (0.2%)40 (5.2%)196 (24.1%)129 (26.9%)118 (21.9%)22 (18.0%) INFECTION, NON-CMV81 (19.8%)280 (36.4%)188 (23.2%)92 (19.2%)94 (17.4%)16 (13.1%) GRAFT FAILURE128 (31.3%)164 (21.3%)153 (18.8%)98 (20.5%)112 (20.8%)28 (23.0%) 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141